Pembrolizumab generates meaningful efficacy in a subset of patients treated beyond RECIST v1.1 progression

Vivek Subbiah shared on LinkedIn:

“Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression

Authors: Brian G. Topp, Madhav Channavazzala, Kapil Mayawala, Dinesh P. De Alwis, Eric Rubin, Alexandra Snyder, Jedd D. Wolchok, Antoni Ribas

While many patients are treated beyond progression (TBP), the magnitude and duration of clinical benefit in these patients have not been fully quantified.

Interesting study published in Cancer cell shows that

Pembrolizumab generates meaningful efficacy in a subset of patients treated beyond RECIST v1.1 progression.”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.